

ASH CLINICAL PRACTICE GUIDELINES VENOUS THROMBOEMBOLISM (VTE)



Treatment of Venous Thromboembolism: Thrombophilia Testing

An Educational Slide Set

American Society of Hematology Guidelines for the Management of Venous Thromboembolism: Thrombophilia Testing

Slide set authors:

Taylor Dear, MD (University of Toronto) Nicole Relke, MD (University of Toronto) Zachary Liederman, MD MScCH (University of Toronto) Saskia Middeldorp, MD, PhD (Radboud University Medical Center)



Clinical Guidelines

American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing

Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, Coppens M, Houghton D, James A, Lang E, Moll S, Myers T, Bhatt M, Chai Adisaksopha C, Colunga Lozano LE, Karam SG, Zhang Y, Wiercioch W, Schünemann HJ, Iorio A

CLINICAL GUID	ELINES	Blood advances
	ciety of Hematology 202 romboembolism: thromb	3 guidelines for management ophilia testing
Eddy Lang, ¹⁰ Stephan I		fichiel Coppens, ^{6,6} Damon Houghton, ^{7,8} Andra H. James, ⁹ hai-Adisaksopha, ¹³ Luis E. Colunga-Lozano, ¹⁴ Samer G. Karam, ^{2,3} d Alfonso lorio ³
⁹ Department of Health Resear Versiti Blood Research Institut Amst extam, The Netherlands; Department of Caterics and Department of Obstetrics and Calgay, Calgay, AB, Cana Canada; ¹⁰ Division of Hemato	ch Methoda, Exidence, and Impact, McMatater Uriversty, le us Versit and Medical College of Wincenste, Minesulee, V ⁴ Pulmonary Hypestension and Thrombosik, Amsterdam Can Diseases and ⁴ Division of Hermatology, Department of Inte Signocology, Dula University School of Medicine, Jouhan, N da: ¹¹ Division of Hermatology, Department of Medicine, Jouhan, N da: ¹¹ Division of Hermatology, Department of Medicine, School 1990, Department of Hermatology, Departm	hetanski, "Akhalel G. DeGootd Cochano Canada and MacGRADE Centre and minon, QK Canada, "Department of Medicina, Division of Humabidgy & Onoblay, Ri-"Department of Wandari Anntendam UWC, University of Ansterdam, Ri-Boscatti Sciences, Ameridam, The Netherlands, "Division of Mannai-Healt Medicine, mail Medicine, Mayo Chric, Rochaster, UNI: "Division of Mannai-Healt Medicine, mail Medicine, Mayo Chric, Rochaster, UNI: "Division of Mannai-Healt Medicine, Ci," "Department of Emergency Medicine, Curreing School of Medicine, University warity of North Canzina School of Medicine, Chapat Hil, NC, "Cambridge, OR, Chang Mail University, Chang Mai, Thailand," "Health Sciences Conter, Universitäd neter and Faculty of Medicine, University of Freiburg, Ferburg, Germany
		ured thrombophilia are risk factors for venous thromboembolism e management decisions is controversial.
	Objective: These evidence-based to support decision making about	guidelines from the American Society of Hematology (ASH) intend thrombophilia testing.
	expertise and minimizing bias fro provided logistical support, perform to-decision tables. The Grading	fisciplinary guideline panel covering clinical and methodological m conflicts of interest. The McMaster University GRADE Centre de systematic reviews, and created evidence profiles and evidence- of Recommendations Assessment, Development, and Evaluation commendations were subject to public comment.
		recommendations regarding thrombophilia testing and associated ndations are based on very low certainty in the evidence due to
	before starting combined oral co bophilia testing in the following s transient or hormonal risk factors;	a strong recommendation against testing the general population traceptives (COCe) and conditional recommendations for throm- cenarios: (a) patients with VTE associated with nonsurgical major (b) patents with cerebral or splanchnic venous thrombosis, in set- otherwise be discontinued; (c) individuals with a family history of

tings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophytaxis for minor proowing risk factors and for guidance to avoid CO2/ahromone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for formobophila.

Summary of recommendations

For each of the clinical questions for patients with venous thromboembolism (VTE), the panel compared 2 scenarios: (a) thrombophilia testing and subsequent indefinite anticcagulation of only the individuals

Submitted 13 March 2023; accepted 4 May 2023; prepublished online on Blood Advances Fist: Edition 17 May 2023; final version published online 28 November 2023. https://doi.org/10.1180/bloodschemcess.2023010197. Data are available through ASHVMcMaster Unkersity GRADE Centre. The 41-bet were under of this article centralise a data supplement.

© 2023 by The American Society of Hematology. Licensed under Creative Commons Ambution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights mesered.

28 NOVEMBER 2023 - VOLUME 7, NUMBER 22



ASH Clinical Practice Guidelines on VTE

- 1. Prevention of VTE in Surgical Hospitalized Patients
- 2. Prevention of VTE in Medical Hospitalized Patients
- 3. Diagnosis of VTE
- 4. Optimal Management of Anticoagulant Therapy
- 5. Heparin-Induced Thrombocytopenia (HIT)
- 6. VTE in the Context of Pregnancy

7. Thrombophilia Testing

- 8. Treatment of Pediatric VTE
- 9. Treatment of Acute VTE (DVT and PE)
- 10. Prevention and Treatment of VTE in Patients with Cancer
- 11. Anticoagulation in Patients with COVID-19
- 12. Adaptation of ASH Management of VTE Guidelines for Latin America





How were these ASH guidelines developed?

PANEL FORMATION

Each guideline panel was formed following these key criteria:

- Balance of expertise (including disciplines beyond hematology, and patients)
- Close attention to minimization and management of COI

CLINICAL QUESTIONS

20-30 clinically-relevant questions generated in PICO format (population, intervention, comparison, outcome)

Example: PICO question

"Should thrombolytic therapy in addition to anticoagulation vs. anticoagulation alone be used for patients with extensive proximal DVT??"

EVIDENCE SYNTHESIS

Evidence summary generated for each PICO question via systematic review of health effects plus:

- Resource use
- Feasibility
- Acceptability
- Equity
- Patient values and preferences

MAKING RECOMMENDATIONS

Recommendations made by guideline panel members based on evidence for all factors.

ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources, such as this slide set, derived from guidelines that require updating are removed from the ASH website.





	STRONG Recommendation ("The panel recommends…")	CONDITIONAL Recommendation ("The panel suggests")
For patients	Most individuals would want the intervention.	A majority would want the intervention, but many would not.
For clinicians	Most individuals should receive the intervention.	Different choices will be appropriate for different patients, depending on their values and preferences. Use shared decision making .





Grading the quality of evidence





Introduction

Thrombophilia: acquired or hereditary conditions with higher-than-normal risk of VTE Thrombophilia testing has several potential advantages and disadvantages:

Advantages	Disadvantages
Improved risk stratification of VTE	Risk of false negatives (missed diagnosis) and false positives (overdiagnosis)
Guides treatment and prevention of VTE	Potential for physical, psychological, or financial harm to patients

Guideline purpose: Provide evidence-based recommendations about whether thrombophilia testing and tailoring management based on results, improves patient-important outcomes.



Objectives

By the end of the session, you should be able to:

- 1. Review the prevalence and risks associated with hereditary thrombophilia
- 2. Describe when thrombophilia testing may be indicated in patients with symptomatic VTE
- 3. Describe recommendations for thrombophilia testing in asymptomatic patients with a family history of VTE/thrombophilia




For each clinical question, the panel compared two scenarios:

Thrombophilia Testing Intervention in only the individuals found to have the thrombophilia

No thrombophilia Testing Usual care in all individuals

Depending on the specific question, for patients positive for thrombophilia, interventions include:


- Indefinite Anticoagulation
- Thromboprophylaxis
- Avoidance of Thrombotic Risk Factor







For example, in a patient with a history of a provoked VTE, where stopping anticoagulation is usual care:



In providing a recommendation, the panel considered:

- Risk of bleeding vs. recurrent thrombosis
- Cost & burden of thrombophilia testing/anticoagulant treatment
- Patient preferences





Thrombophilia testing in patients with VTE

	Prevalence, Median % (Min-Max)	RR for VTE Recurrence - Positive vs Negative (95% CI)	Treatment effect for VTE recurrence, RR (95% CI)	Treatment effect for major bleeding, RR (95% CI)
Any Thrombophilia	38.0 (21.6-59.5)	1.65 (1.28-2.47)		
	Low Risk			
FVL Heterozygous	17.5 (4.1-34.8)	1.36 (1.19-1.57)		
Prothrombin gene mutation	6.1 (1.4-16.3)	1.34 (1.05-1.71)		
High Risk			0.15	2.17
FVL Homozygous	1.5 (0.3-3.1)	2.10 (1.09-4.06)	(0.10-0.23)	(1.40-3.35)
Antithrombin (AT) Deficiency*	2.2 (0.2-8.7)	2.07 (1.50-2.87)		
Protein C (PC) Deficiency*	2.5 (0.7-8.6)	2.13 (1.26-3.59)		
Protein S (PS) Deficiency *	2.3 (0.7-7.3)	1.30 (0.87-1.94)		

*Results influenced by hormone use, timing of testing and anticoagulation



Case 1: Unprovoked VTE

52 year old male

Past Medical History: None

Diagnosis: Unprovoked symptomatic right leg DVT

Treatment: He has been treated with anticoagulation for 3 months without any bleeding concerns



Usual Care

Indefinite antithrombotic therapy is suggested in most individuals with unprovoked VTE (Treatment of VTE ASH guideline)

Thrombophilia testing strategy would mean that patients without thrombophilia would stop anticoagulant therapy (potential for more thrombosis and less bleeding)

What management strategy do you suggest?

- a. No thrombophilia testing and indefinite anticoagulation
- b. Thrombophilia testing and stop anticoagulation in patients without thrombophilia





In patients with **unprovoked VTE** who have completed primary short term treatment, the ASH guideline **panel suggests not to perform thrombophilia testing to guide the duration of anticoagulant treatment** (conditional recommendation, low certainty)

Outcomes	Impact of thrombophilia testing strategy per 1000 patients (620 fewer patients treated with indefinite anticoagulation)	
Recurrent VTE	42 more VTE recurrences (ranging from 17 to 67)	
 Major Bleeding - Low Risk (0.5% per year) 	4 fewer major bleeds (ranging from 1 to 9)	
 Major Bleeding – High Risk (1.5% per year) 	11 fewer major bleeds (ranging from 2 to 28)	





35-year-old female

Past Medical History: Hypertension

Past Surgical History: Appendectomy

Diagnosis: Pulmonary embolism on post-operative day 21 following appendectomy

Treatment: She is started on anticoagulation and referred for outpatient assessment



Usual Care

Individuals with VTE provoked by surgery discontinue anticoagulant therapy after primary treatment (Treatment of VTE ASH guideline)

Thrombophilia testing strategy would mean that patients with thrombophilia would receive indefinite anticoagulant therapy (potential for less thrombosis and more bleeding)

What management strategy do you suggest?

- a. No thrombophilia testing, treat for 3 months and stop anticoagulation
- b. Thrombophilia testing and indefinite anticoagulation only in patients with thrombophilia





Recommendation 2

In patients with VTE provoked by surgery who have completed primary short-term treatment, the ASH guideline panel suggests not to perform thrombophilia testing to determine the duration of anticoagulation treatment (conditional recommendation, very low certainty of evidence)

Outcomes	Impact of thrombophilia testing strategy per 1000 patients (380 more patients treated with indefinite anticoagulation)	
Recurrent VTE	4 fewer VTE recurrences (ranging from 2 to 7)	
Major Bleeding - Low Risk (0.5% per year)	2 more major bleeds (ranging from 0 to 7)	
Major Bleeding - High Risk (1.5% per year)	7 more major bleeds (ranging from 1 to 21)	





24-year-old female, G1P0, 35+3 weeks gestation

Past Medical History: None

Diagnosis: Left leg DVT after presenting with a 2-day history of increasing left leg swelling and pain

Treatment: She is started on anticoagulation and referred for outpatient assessment



Usual Care

Individuals with VTE provoked by pregnancy will discontinue anticoagulant therapy after primary treatment (Treatment of VTE ASH guideline)

Thrombophilia testing strategy would mean that patients with thrombophilia would receive indefinite anticoagulant therapy (potential for less thrombosis and more bleeding)

What management plan do you suggest?

a. No thrombophilia testing, treat for 3 months and stop anticoagulation

b. Thrombophilia testing and indefinite anticoagulation only in patients with thrombophilia



Case 4: Non-Surgical Major Transient Risk Factor

64-year-old male

Past Medical History: None

Medications: Naproxen PRN

Diagnosis: Left leg DVT diagnosed on day 3 of admission for pneumonia. While in hospital he is relatively immobile, only getting up to use the washroom

Treatment: He is started on anticoagulation and referred for outpatient assessment



Usual Care

Individuals with VTE provoked by non-surgical major transient risk factors will discontinue anticoagulant therapy after primary treatment (Treatment of VTE ASH guideline)

Thrombophilia testing strategy would mean that patients with thrombophilia would receive indefinite anticoagulant treatment (potential for less thrombosis and more bleeding)

What management plan do you suggest?

- a. No thrombophilia testing, treat for 3 months and stop anticoagulation
- b. Thrombophilia testing and indefinite anticoagulation only in patients with thrombophilia





Recommendations 3-5

In patients with VTE provoked by a non-surgical major transient risk factor, combined oral contraceptives, pregnancy or postpartum who have completed primary short-term treatment, the panel suggests testing for thrombophilia to guide anticoagulant treatment duration (conditional recommendation, very low certainty)

Outcomes	Impact of thrombophilia testing strategy per 1000 patients (380 more patients treated with indefinite anticoagulation)	
Recurrent VTE	21 fewer VTE recurrences (ranging from 10 to 35)	
Major Bleeding - Low Risk (0.5% per year)	2 more major bleeds (ranging from 0 to 7)	
Major Bleeding - High Risk (1.5% per year)	7 more major bleeds (ranging from 1 to 21)	





Transient Risk Factors (resolve after provoked VTE)

- Major Risk Factor
- Surgery, gen anesthesia > 30 min
- Confined to hospital bed ≥ 3 days with acute illness
- Cesarean section

Minor Risk Factor

- Estrogen therapy (OCP, HRT)
- Pregnancy, puerperium
- Confined to bed out of hospital ≥ 3 days with acute illness
- Leg injury, reduced mobility \geq 3 days

Chronic (Persistent) Risk Factors (persistent after VTE occurs)

- Active cancer (ongoing chemo; recurrent or progressive disease)
- Inflammatory bowel disease
- Autoimmune disorder (e.g., antiphospholipid syndrome, rheumatoid arthritis)
- Chronic infection
- Chronic immobility (e.g., spinal cord injury)





44-year-old male assessed in follow up

Past Medical History: Hypertension

Diagnosis: Unprovoked cerebral venous thrombosis diagnosed 2 years earlier

Treatment: In discussion with the patient, you have decided to continue with indefinite anticoagulation





Thrombophilia testing strategy impact is dependent on clinicians' usual care.

Primary short term treatment only planned – patients with thrombophilia would receive indefinite anticoagulant treatment (potential for less thrombosis and more bleeding)

Indefinite anticoagulation planned – patients without thrombophilia would stop anticoagulant therapy (potential for more thrombosis and less bleeding)

The patient is interested in thrombophilia testing.

What management plan do you suggest?

- a. No thrombophilia testing and indefinite anticoagulation
- b. Thrombophilia testing and stop anticoagulation if negative





Recommendations 7-8

In patients with Cerebral Venous Thrombosis who have completed primary short-term treatment, the panel suggests testing for thrombophilia to guide anticoagulant treatment duration only if anticoagulation would be discontinued otherwise (conditional recommendation, very low certainty)

	Impact of thrombophilia test		Additional factors may	
Outcomes	Primary treatment only planned (436 more patients treated with indefinite anticoagulation)	Indefinite anticoagulant therapy planned (564 fewer patients treated with indefinite anticoagulation)	ndefinite anticoagulant therapy planned fewer patients treated with	
Recurrent VTE	18 fewer VTE recurrences (14 to 23)	14 more VTE recurrences (10 to 18)		 Provoked vs. unprovoked
Major Bleeding - Low Risk	3 more major bleeds (1 to 5)	3 fewer major bleeds (1 to 7)	-	Additional thrombophilia (e.g.
Major Bleeding - High Risk	8 more major bleeds (3 to 16)	10 fewer major bleeds (3 to 20)	-	JAK 2 mutation)





Summary of Thrombophilia Testing Strategy for Patients with VTE

	Base Risk of VTE Recurrence (1 st year)	Treatment Risk for Major Bleeding	Recommended Strategy for Thrombophilia Testing
Unprovoked	High (10%)		Do Not Test (indefinite anticoagulation in all)
Unusual Site	Intermediate (2.7%-3.8%)	0.5-1.5%	Do Not Test (indefinite anticoagulation in all) OR Test (indefinite anticoagulant therapy in patients with thrombophilia)
Provoked (non-surgical)	Intermediate (5%)	0.5 1.570	Test (indefinite anticoagulant therapy in patients with thrombophilia)
Provoked (surgical)	Low (1%)		Do Not Test (primary short-term anticoagulation in all)





Introduction to thrombophilia testing in individuals with a family history of VTE and/or thrombophilia

In families with VTE, the panel examined patient outcomes from testing asymptomatic individuals (relatives) for thrombophilia

The panel considered two scenarios:

- 1. Known specific thrombophilia in affected family member (proband)
 - Selective thrombophilia testing
- 2. Unknown thrombophilia status
 - Panel thrombophilia testing

When outcomes were similar, the panel favored selective over panel testing



Thrombophilia testing in individuals with family history of VTE

	RR for 1 st VTE - Positive vs Negative (95% CI)	Treatment effect for VTE occurrence, RR (95% CI)	Treatment effect for major bleeding, RR (95% CI)
Low Risl	ĸ		
FVL Heterozygous	2.71 (2.06-3.56)		
Prothrombin (PT) Mutation	2.35 (1.46-3.78)		
High Risk		0.54 (0.32-0.91)	2.09
Antithrombin (AT) Deficiency	12.17 (5.45-27.17)	(0.52-0.91)	(1.33-3.27)
Protein C (PC) Deficiency	7.47 (2.81-19.81)		
Protein S (PS) Deficiency	5.98 (2.45-14.57)		

Panel Testing: testing for APLA and all hereditary thrombophilia types

Selective Thrombophilia Testing: testing for a specific thrombophilia type (i.e. family testing)





Case 6: Family history of VTE and minor provoking risk factor

22-year-old female is assessed as an outpatient following a severe high grade ankle sprain being managed non-operatively. Non-weightbearing and immobilization are recommended for the next 10 days

Past Medical History: None

Medications: None

Family History: Mother has a history of DVT. To her knowledge, her mother has not been tested for thrombophilia



Usual Care

No thromboprophylaxis for medical outpatients with minor provoking risk factors for VTE (Prophylaxis for Medical Patients ASH guideline)

Thrombophilia testing strategy would mean that individuals with thrombophilia would receive thromboprophylaxis for a minor provoking factor (potential for less thrombosis and more bleeding)

What management plan do you suggest?

- a. No thrombophilia testing and no thromboprophylaxis
- b. Thrombophilia testing and start anticoagulant thromboprophylaxis if positive



Recommendation 13

In individuals with a minor risk factor who have a family history of VTE and unknown thrombophilia status, suggest not to perform thrombophilia testing to guide thromboprophylaxis (conditional recommendation, very low certainty)

Outcomes	Impact of thrombophilia testing strategy in first degree relatives of patients with VTE per 1000 episodes (142 more patients receive thromboprophylaxis)	Recommendations assume no time delay for testing
Recurrent VTE	2.16 fewer VTE (0.02 to 5.66)	
Major Bleeding	0.62 more major bleeds (0.13 to 1.82)	





Recommendations 11-12

In individuals with a minor provoking risk factor who have a family history of VTE and known thrombophilia, suggest thrombophilia testing to guide thromboprophylaxis for high risk thrombophilia but not low risk thrombophilia (conditional recommendation, very low certainty)

Family History	Impact of selective thrombophilia strategy in first degree relatives of patients with VTE per 1000 episodes (500 more patients treated with thromboprophylaxis)				
	VTE		Major Bleeding		
	Lo				
FVL Heterozygous		5.04 fewer VTE (0.91 to 7.96)			
Prothrombin mutation	n 4.84 fewer VTE (0.80 to 8.07)				
High Risk			2.18 more bleeds		
Antithrombin Deficien	су	21.25 fewer VTE (3.80 to 32.79)	(0.66 to 4.54)		
Protein C Deficiency		20.28 fewer VTE (3.32 to 32.37)	_		
Protein S Deficiency		19.79 fewer VTE (3.20 to 31.82)			






Case 7: Combined Oral Contraceptive (COC) pill or Hormone Replacement Therapy (HRT) use

The same patient is re-referred 2 years later. She would like to start the combined oral contraceptive pill for pregnancy prevention

Her past medical history is unchanged and she is not on any regular medications

Since the initial visit, her sister developed an unprovoked PE and was found to have Protein C Deficiency





She is looking to start combined oral contraceptive pill for prevention of pregnancy.

What management plan do you suggest?

- a. No thrombophilia testing and start COC
- b. Thrombophilia testing and suggest against COC if positive





Recommendations 19-20

In individuals with a **family history of VTE and known thrombophilia**, **suggest selective thrombophilia testing** to guide **COC** or **HRT for high risk thrombophilia only** (conditional recommendation, very low certainty)

Family History	Impact of selective thrombophilia testing strategy on VTE episodes per 100 women who are first degree relatives of patients with VTE / year (500 fewe using COC or HRT)*	
	COC	HRT
Low Risk		
FVL Heterozygous	4.57 fewer VTE (3.75 to 5.55)	1.36 fewer VTE (0.21 to 1.96)
Prothrombin mutation	4.38 fewer VTE (3.76 to 4.90)	2.20 fewer VTE (0.25 to 4.79)
н	igh Risk	
Antithrombin Deficiency	19.39 fewer VTE (15.30 to 23.90)	6.45 fewer VTE (0.77 to 13.49)
Protein C Deficiency	13.84 fewer VTE (11.34 to 15.45)	4.94 fewer VTE (0.60 to 10.12)
Protein S Deficiency	10.49 fewer (8.71 to 11.48)	3.92 fewer VTE (0.47 to 7.87)





Recommendations 15-18

In individuals from the **general population** suggest **not to perform thrombophilia testing** to guide the use of **COC** (strong recommendation, low certainty) or **HRT** (conditional recommendation, low certainty) In individuals with a **family history of VTE and unknown thrombophilia**, suggest **not to perform thrombophilia testing** to guide the use of **COC** or **HRT** (conditional recommendation, very low certainty)

	Impact of thrombophilia testing strategy on VTE per 1000 women / year (69-142 fewer using COC or HRT)*	
	СОС	HRT
General Population	0.26 fewer VTE (0.09 to 0.65)	0.29 fewer VTE (0.01 to 1.98)
Family History of VTE (1st degree) and Unknown Thrombophilia	1.17 fewer VTE (0.06 to 1.55)	0.94 fewer VTE (0.01 to 5.16)

The potential harms of hormone avoidance fall outside the guidelines scope but may include unwanted pregnancies and postmenopausal symptoms.





Case 8: Women who are planning pregnancy

26 year old female is planning to become pregnant, and was referred for a family history of VTE and FVL. The patient has not undergone testing for thrombophilia, and she has no history of VTE

Past Medical History: None

Medications: None

Family History: Sister has a history of DVT and is homozygous for FVL



Usual Care

No antepartum or postpartum thromboprophylaxis for women with no or 1 clinical risk factor (Pregnancy ASH guideline)

Thrombophilia testing strategy would mean that patients with thrombophilia would receive antepartum and/or postpartum thromboprophylaxis (potential for less thrombosis and more bleeding) She is planning a pregnancy.

What management plan do you recommend?

- a. Test for all inherited thrombophilias (FVL, PGM, Protein C / S, ATIII) and start thromboprophylaxis if positive
- b. No inherited thrombophilia testing and do not start thromboprophylaxis
- c. Selective thrombophilia testing (FVL only) and start thromboprophylaxis if FVL homozygous





In women with a **family history of VTE and homozygous FVL, combination of FVL and PGM, or antithrombin deficiency in the family**, suggest **testing for the known familial thrombophilia** and **antepartum thromboprophylaxis in women with the same familial thrombophilia** (conditional recommendation, very low certainty)

Family History	Impact of selective thrombophilia testing strategy per 1000 pregnancies (Antepartum thromboprophylaxis used in 250-500* more pregnancies)	
Homozygous FVL	19.35 fewer VTE (12.16 to 24.14)	1.05 fewer bleeds
Combination of FVL and PGM	9.05 fewer VTE (4.63 to 12.33)	(1.52 fewer to 3.50 more)
Antithrombin deficiency	9.70 fewer VTE (5.90 to 11.97)	2.09 fewer bleeds (3.04 fewer to 7.01 more)
Protein C deficiency	2.02 fewer VTE (0.82 to 2.66)	
Protein S deficiency	3.94 fewer VTE (1.34 to 5.32)	

In women with a family history of VTE and known protein C or S deficiency in the family, the panel suggests either testing or not testing to guide antepartum prophylaxisO

*250 more pregnancies for family history of homozygous FVL or combination of FVL and PGM; 500 more pregnancies for family history of antithrombin deficiency, protein C deficiency or protein S deficiency





Recommendation 22

In women with a family history of VTE and a high risk thrombophilia (including combination of FVL and PGM), suggest testing for the known familial thrombophilia and postpartum thromboprophylaxis in women with the same **familial thrombophilia** (conditional recommendation, very low certainty)

Family History	Impact of thrombophilia strategy per 1000 pregnancies (Postpartum thromboprophylaxis used in 250-500* more pregnancies)		ASI ma
Homozygous FVL	19.35 fewer VTE (12.16 to 24.14)	1.06 fewer bleeds	pre pos
Combination of FVL and PGM	9.05 fewer VTE (4.63 to 12.33)	(3.51 fewer to 10.07 more)	thrombo prevent
Antithrombin deficiency	9.70 fewer VTE (5.90 to 11.97)	0.53 fewer bleeds (1.76 fewer to 5.03 more)	ind het
Protein C deficiency	2.02 fewer VTE (0.82 to 2.66)		
Protein S deficiency	3.94 fewer VTE (1.34 to 5.32)		

delines on the ment of VTE in ncy suggest against tum oprophylaxis to a first VTE in als with FVL ygosity or PGM

*250 more pregnancies for family history of homozygous FVL or combination of FVL and PGM; 500 more pregnancies for family history of antithrombin deficiency, protein C deficiency or protein S deficiency





Case 9: Patients with cancer and family history VTE

65 year old man from home with stage II head and neck cancer is seen in clinic before starting systemic chemotherapy

Past Medical History: Hypertension

Medications: Ramipril

Family History: Brother has a history of pulmonary embolism



Usual Care

No thromboprophylaxis for ambulatory cancer patients receiving systemic therapy at low to intermediate risk of thrombosis (Prevention and Treatment in Patients with Cancer ASH Guideline)

Thrombophilia testing strategy would mean that patients with thrombophilia would receive thromboprophylaxis (potential for less thrombosis and more bleeding)

What management plan do you recommend before starting systemic chemotherapy?

- a. No thrombophilia testing and do not start thromboprophylaxis
- b. Testing for hereditary thrombophilia and thromboprophylaxis if positive





Recommendation 23

In **ambulatory cancer patients** receiving systemic therapy who have a **family history of VTE and are at low or intermediate risk for VTE**, the panel **suggests testing for hereditary thrombophilia** and starting thromboprophylaxis if positive (conditional, very low certainty)

Impact of thrombophilia testing strategy per 1000 patients		
who are first degree relatives of patients with VTE/ 6 months		
(142 more patients receive thromboprophylaxis)		

	VTE	Major Bleeding
Low Risk for VTE	6.85 fewer VTE (23.37 fewer to 0.16 more)	0.33 more bleeds (0.10 fewer to 2.02 more)
Intermediate Risk for VTE	9.04 fewer VTE (30.85 fewer to 0.21 more)	0.74 more bleeds (0.22 fewer to 4.49 more)

ASH VTE Cancer guidelines suggest using direct oral anticoagulant (DOAC) prophylaxis in all ambulatory cancer patients receiving systemic therapy with high VTE risk



Other guideline recommendations that were not directly covered in this session

Thrombophilia testing for:

- Unspecified VTE (Recommendation 6)
- Splanchnic vein thrombosis (Recommendations 9-10)
- Family history of thrombophilia but no family history of VTE to prevent VTE associated with minor risk factors (Recommendation 14)



Future Priorities for Research

- Risk of recurrent VTE and its association with prognostic variables
- Optimal duration of anticoagulant therapy after acute cerebral venous thrombosis or acute splanchnic venous thrombosis
- Large implementation studies comparing the impact (outcomes rates) among management strategies involving thrombophilia testing
- Online calculator for specific thrombophilia defects incorporating localized prevalence values



In Summary: Back to Our Objectives

- 1. Review the prevalence and risks associated with hereditary thrombophilia
- 2. Describe when thrombophilia testing may be indicated in patients with symptomatic VTE
- 3. Describe recommendations for thrombophilia testing in asymptomatic patients with a family history of VTE/thrombophilia